Disclosure of Editors’ Financial Relationships

This article has been corrected.

VIEW CORRECTION

Publication: American Journal of Psychiatry

Volume 180, Number 4

https://doi.org/10.1176/appi.ajp.23180003

PDF/EPUB

The American Journal of Psychiatry requires its editors to disclose any financial relationships with commercial interests, including consulting with pharmaceutical companies or receiving honoraria from them. These relationships were as follows:

Ned H. Kalin, M.D. (Editor-in-Chief): Dr. Kalin reports serving as a consultant to the Board of Scientific Advisors, Pritzker Neuropsychiatric Disorders Consortium; Skyland Trail National Advisory Board, CME Outfitters, LLC, Corcept Therapeutics Incorporated, and the Institute for Early Adversity Research External Scientific Advisory Board at the University of Texas-Austin.

Elisabeth B. Binder, M.D., Ph.D. (Deputy Editor): Dr. Binder reports no financial relationships with commercial interests.

Kathleen T. Brady, M.D., Ph.D. (Deputy Editor): Dr. Brady reports serving as a consultant to Alkermes Pharmaceuticals, Embera Pharma, Genomind, Indivior Pharmaceuticals, Sage Pharmaceuticals, Skyland Trail Treatment Center.

David A. Lewis, M.D. (Deputy Editor): Dr. Lewis reports currently receiving investigator-initiated research support from Merck.

William M. McDonald, M.D. (Deputy Editor): Dr. McDonald reports receiving compensation as the Chair of the Data and Safety Monitoring Board for an NIA-sponsored multicenter study; serving on the Board of Skyland Trail and 3Keys; serving as a consultant for Sage Therapeutics and Signant Health; and receiving past funding from Cervel Neurotherapeutics, NeoSync, Neuronetics, Soterix, and the Stanley Foundation.

Daniel S. Pine, M.D. (Deputy Editor): Dr. Pine reports no financial relationships with commercial interests.

Carolyn Rodriguez, M.D., Ph.D. (Deputy Editor): Dr. Rodriguez reports in the past 3 years having served as a consultant to Biogen, Biohaven Pharmaceuticals, Epiodyne, and Osmind; receiving grant support from Biohaven Pharmaceuticals; and receiving royalties from American Psychiatric Association Publishing. [Updated online on May 12, 2023.]

Information & Authors

Information

Published In

American Journal of Psychiatry

Volume 180 • Number 4 • April 01, 2023

Pages: 319

PubMed: 37010362

History

Published in print: April 01, 2023

Published online: 3 April 2023

Authors

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format	RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks
Direct importt
Citation style
Style

Copy to clipboard
Tips for downloading citations

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR^® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Disclosure of Editors’ Financial Relationships